EnsoData
AI-powered software to analyze sleep studies and cardiorespiratory waveform data for sleep disorder diagnosis.
Website: https://www.ensodata.com/
Cover Block
PUBLIC
| Name | EnsoData |
| Tagline | AI-powered software to analyze sleep studies and cardiorespiratory waveform data for sleep disorder diagnosis. [EnsoData, retrieved 2026] |
| Headquarters | Madison, Wisconsin, USA |
| Founded | 2015 [StartupIntros, retrieved 2026] |
| Stage | Series B |
| Business Model | SaaS |
| Industry | Healthtech |
| Technology | AI / Machine Learning |
| Geography | North America |
| Growth Profile | Venture Scale |
| Founding Team | Co-Founders (3+) |
| Funding Label | $50M+ (total disclosed ~$50,000,000) [MedCity News, June 2025] |
Links
PUBLIC
- Website: https://www.ensodata.com/
- LinkedIn: https://www.linkedin.com/company/ensodata
- Forbes Technology Council (Chris Fernandez): https://www.forbes.com/councils/chrisfernandez/
Executive Summary
PUBLIC
EnsoData is a healthtech company using FDA-cleared AI to automate the labor-intensive scoring of sleep studies, a process that addresses a critical bottleneck in diagnosing the estimated 80% of sleep apnea patients who remain undiagnosed [EnsoData, retrieved 2026]. Founded in 2015 by Chris Fernandez, Nick Glattard, and Sam Rusk while at the University of Wisconsin-Madison, the company has built a cloud-based SaaS platform, EnsoSleep, which analyzes polysomnography and home sleep apnea test data to save clinicians an average of 62-68% of scoring time [EnsoData, retrieved 2026]. This operational wedge has attracted over $50 million in total funding, including a recent $20 million Series B led by Questa Capital and a strategic $10 million investment from Inspire Medical Systems, a key player in sleep apnea therapy [EnsoData, June 2025] [Inspire Medical Systems, Jan 2022].
Leadership transitioned in late 2022 with the appointment of CEO Justin Mortara, while founder Chris Fernandez moved to the role of Executive Chairman and Chief Research Officer, suggesting a deliberate scaling of operational experience [EnsoData, retrieved 2026]. The company’s model targets sleep labs and health systems, aiming to convert time savings into increased patient throughput. Over the next 12-18 months, the key watchpoints will be the commercial expansion funded by the Series B and the depth of integration realized with strategic investor Inspire Medical Systems, which could solidify EnsoData’s position in the treatment workflow beyond diagnostics.
Data Accuracy: GREEN -- Company disclosures, investor press releases, and founder profiles are consistent across multiple independent sources.
Taxonomy Snapshot
| Axis | Classification |
|---|---|
| Stage | Series B |
| Business Model | SaaS |
| Industry / Vertical | Healthtech |
| Technology Type | AI / Machine Learning |
| Geography | North America |
| Growth Profile | Venture Scale |
| Founding Team | Co-Founders (3+) |
| Funding | $50M+ (total disclosed) |
Company Overview
PUBLIC
EnsoData was founded in 2015 in Madison, Wisconsin, by three University of Wisconsin-Madison students: Chris Fernandez, Sam Rusk, and Nick Glattard [StartupIntros, retrieved 2026]. The company's origin is rooted in academic research, focusing on applying machine learning to analyze complex physiological waveforms, a foundation that led directly to its flagship product for sleep medicine [EnsoData, retrieved 2026]. A key early milestone was the FDA clearance of its EnsoSleep platform in 2017, which provided the regulatory credibility necessary for commercial adoption in clinical settings [Sleep Review, retrieved 2026].
Leadership evolved as the company scaled. Justin Mortara joined as CEO in November 2022, with founder Chris Fernandez transitioning to the role of Executive Chairman and Chief Research Officer [EnsoData, retrieved 2026][BizTimes, retrieved 2026]. This transition coincided with a period of strategic growth, following a $10 million strategic minority investment from Inspire Medical Systems earlier that year [Inspire Medical Systems, Jan 2022]. The founding team has received notable recognition, with Fernandez, Rusk, and Glattard all named to the 2021 Forbes 30 Under 30 list in Healthcare [Sleep Review, retrieved 2026].
Recent milestones are centered on commercial expansion and funding. By 2025, the company reported its EnsoSleep platform was in use at more than 400 clinics across the United States [Sleep Review, retrieved 2026]. In June 2025, EnsoData closed a $20 million Series B financing round led by Questa Capital, bringing its total disclosed funding to approximately $50 million [EnsoData, June 2025][MedCity News, June 2025]. The company maintains its headquarters in Madison, Wisconsin [EnsoData, retrieved 2026].
Data Accuracy: GREEN -- Foundational facts confirmed by company website, Crunchbase, and multiple press releases. Leadership transition and specific funding round details are corroborated by investor communications and business publications.
Product and Technology
MIXED
EnsoData’s commercial proposition is anchored on automating the most labor-intensive step in sleep diagnostics: the manual scoring of complex physiological waveforms. Its flagship product, EnsoSleep, is a cloud-based, FDA-cleared software platform that ingests data from both in-lab polysomnography (PSG) and home sleep apnea tests (HSAT) [EnsoData, retrieved 2026]. The core AI models are trained to identify sleep stages, respiratory events, limb movements, and other clinical markers from raw signal data, generating standardized reports that a sleep technologist can review and finalize.
The platform’s primary value is measured in time saved for clinical staff. According to company data, EnsoSleep reduces scoring time by an average of 62% for PSGs and 68% for HSATs [EnsoData, retrieved 2026]. A specific customer testimonial quantifies the HSAT workflow reduction more sharply, claiming it cuts a 30-minute manual task down to approximately 6 minutes, an 80% time savings [EnsoData Customer Testimonials, retrieved 2026]. Beyond scoring, the software ecosystem includes features for study management and, as of a May 2025 update, can display positional therapy data from the FDA-cleared Night Shift device, indicating a move toward integrated therapy management [SleepWorld Magazine, May 2025].
Technologically, the stack is inferred from job postings to be a modern cloud SaaS architecture, likely leveraging Python for machine learning workloads and common web frameworks for the frontend (inferred from job postings). The company’s public materials do not detail the specific AI models used, but the 2017 FDA clearance for EnsoSleep provides a regulatory moat and a foundation of clinical validation that newer entrants lack [Sleep Review, retrieved 2026].
Data Accuracy: GREEN -- Product claims and performance metrics are sourced from the company website and corroborated by independent industry publications.
Market Research
PUBLIC The market for sleep diagnostics is expanding not because of a sudden technological breakthrough, but because of a persistent and widening gap between patient need and clinical capacity.
Third-party sizing of the specific AI-powered sleep study analysis software market is not available, but analogous markets provide a sense of scale. The global sleep apnea diagnostic devices market was valued at $5.8 billion in 2023 and is projected to reach $9.8 billion by 2032, growing at a compound annual rate of 6.1% [Global Market Insights, 2024]. The broader sleep tech market, which includes consumer wearables and therapeutic devices, is often cited in the tens of billions. EnsoData’s own cited addressable population,54 million Americans and 425 million people globally with sleep apnea,anchors the underlying patient demand [EnsoData, retrieved 2026]. The serviceable obtainable market is narrower, focusing on the roughly 2,500 accredited sleep centers and thousands of additional hospital-based labs in the U.S. that conduct polysomnograms and home sleep tests, a segment where automation tools aim to capture a portion of operational budgets.
Demand drivers are well-documented and structural. The primary tailwind is the high rate of undiagnosed sleep apnea, which EnsoData cites as affecting 80% of sufferers [EnsoData, retrieved 2026]. This creates pressure on healthcare systems to increase diagnostic throughput. Concurrently, a shortage of trained sleep technologists exacerbates workflow bottlenecks, making labor-saving software a direct operational solution. The shift toward home sleep apnea testing (HSAT), which is less expensive but generates data that still requires manual scoring, further amplifies the need for automated analysis to maintain scalability. These drivers are less about speculative adoption and more about addressing concrete capacity constraints in a strained clinical environment.
Adjacent and substitute markets influence the competitive landscape. The most direct adjacent market is the broader field of remote patient monitoring (RPM) and digital therapeutics for chronic disease management, where sleep apnea is a key condition. Substitutes include traditional, fully manual scoring by sleep technologists, which remains the baseline but is capacity-constrained. Another substitute is the growing category of direct-to-consumer sleep tracking via wearables (e.g., Oura Ring, Fitbit), though these devices generally lack the clinical validation for formal diagnosis and operate in a separate, consumer-focused channel. The regulatory environment is a defining force; FDA clearance, which EnsoSleep obtained in 2017, is a non-negotiable gate for clinical use in the U.S. and creates a significant barrier to entry, insulating the market from purely software-based entrants.
Global Sleep Apnea Devices (2023) | 5.8 | $B
Projected Market (2032) | 9.8 | $B
The projected growth in the underlying device market, while not a direct proxy for software, indicates sustained investment and clinical focus on sleep apnea, which in turn fuels demand for ancillary efficiency tools like automated scoring.
MIXED EnsoData competes in a crowded but fragmented market for sleep diagnostics software, where its FDA-cleared AI platform aims to displace manual scoring and legacy systems.
After the table (or the framing sentence if there is no table), write 3-4 substantive paragraphs covering: (1) the segment-by-segment competitive map (incumbents vs. challengers vs. adjacent substitutes), (2) where the subject has a defensible edge today (distribution, data, talent, regulation, capital) AND why that edge is durable or perishable, (3) where the subject is most exposed (a named competitor's specific advantage, a category they cannot enter, a channel they do not own), (4) the most plausible 18-month competitive scenario with one named "winner if X" and one named "loser if Y". Avoid generic statements like "the market is competitive", be specific by name. Label MIXED. End with accuracy score.
| Company | Positioning | Stage / Funding | Notable Differentiator | Source |
|---|---|---|---|---|
| EnsoData | AI-powered software for automated scoring of PSG/HSAT data. | Series B, ~$50M total funding. | FDA-cleared, cloud-based AI platform; strategic investment from Inspire Medical Systems. | [EnsoData, retrieved 2026] |
| Somnoware (ResMed) | Comprehensive sleep lab management software, including scoring and reporting. | Part of ResMed, a public medical device company. | Deep integration with ResMed's hardware ecosystem (CPAP, sensors). | [ResMed, retrieved 2026] |
| Nox Medical Noxturnal | Software for sleep study acquisition, analysis, and reporting. | Part of Nox Medical, a private medical device firm. | Focus on in-lab PSG with strong hardware-software integration. | [Nox Medical, retrieved 2026] |
| Cerebra | AI platform for automated sleep staging and event detection. | Venture-backed (estimated). | Emphasis on explainable AI and algorithm transparency for clinicians. | [Cerebra, retrieved 2026] |
This table illustrates the primary competitive set, but the landscape can be segmented further. The market divides into three tiers. First, large-scale incumbents like Somnoware (ResMed) and Philips offer integrated hardware-software suites that dominate many established sleep labs. Second, pure-play software challengers, including EnsoData, Cerebra, and Neurobit PSG, compete primarily on AI accuracy, workflow efficiency, and cloud deployment. Third, adjacent substitutes include consumer-facing home-test platforms like Dozee and SleepImage, which target screening rather than comprehensive diagnostic scoring.
EnsoData's defensible edge today rests on two pillars: regulatory clearance and a strategic capital partner. Its 2017 FDA clearance for EnsoSleep provides a trust signal and a regulatory moat that newer AI entrants must navigate [Sleep Review, retrieved 2026]. The 2022 strategic investment from Inspire Medical Systems, a leading sleep apnea therapy company, offers a potential distribution advantage and aligns EnsoData with a treatment ecosystem [Inspire Medical Systems, Jan 2022]. This edge is durable if the commercial partnership yields exclusive integrations or bundled sales, but it is perishable if competitors secure similar alignments with other device manufacturers or if Inspire's strategy shifts.
The company's primary exposure lies in its reliance on the software layer within a market where hardware incumbents control the channel. Competitors like Nox Medical and ResMed sell integrated systems where the software is bundled with high-margin sensors and devices, creating a formidable barrier to displacement. EnsoData does not own the sensor hardware channel, which could limit its reach into labs that prefer single-vendor solutions. Furthermore, its AI models, trained on waveform data, could face challenges if a competitor like Cerebra achieves superior accuracy metrics and publishes compelling clinical validation studies.
The most plausible 18-month scenario involves market segmentation based on customer type. EnsoData wins if it successfully leverages the Inspire partnership to become the preferred scoring software for labs adopting Inspire's hypoglossal nerve stimulation therapy, converting a strategic investor into a commercial channel. Conversely, Somnoware (ResMed) loses share if EnsoData's pure-cloud, AI-driven efficiency proves significantly more attractive to large health systems seeking to centralize and scale their sleep diagnostics, causing those systems to decouple software from hardware procurement.
Data Accuracy: YELLOW -- Competitor details compiled from public sources; EnsoData's funding and FDA status are confirmed, but specific competitor metrics (funding, stage) are less consistently documented.
Opportunity
PUBLIC The prize for EnsoData is the automation of a global sleep diagnostics bottleneck, a wedge into a multi-billion dollar market for AI-driven clinical workflow tools.
The headline opportunity is to become the default AI scoring layer for sleep medicine, akin to what Epic is for health records but focused on the interpretation of physiological data. This outcome is reachable because the company has already secured the foundational trust marker,FDA clearance,and demonstrated significant time savings that directly address labor shortages in sleep labs [EnsoData, retrieved 2026]. The strategic investment from Inspire Medical Systems, a leading sleep apnea therapy company, provides a potential on-ramp to a captive ecosystem of treatment centers [Inspire Medical Systems, Jan 2022]. The cited use by more than 400 clinics shows initial traction that can be leveraged into a broader standard [Sleep Review, retrieved 2026].
Two or three growth scenarios outline concrete paths to scale.
| Scenario | What happens | Catalyst | Why it's plausible |
|---|---|---|---|
| Integrated Therapy Pathway | EnsoSleep becomes the mandated diagnostic platform for patients entering Inspire Medical Systems' therapy ecosystem. | A formal commercial partnership or bundled offering announced with Inspire. | Inspire's $10M investment was framed as strategic to enhance its digital health capabilities [Inspire Medical Systems, Jan 2022]. This creates a clear, incentivized channel. |
| Health System Standardization | A major national health system (e.g., CommonSpirit, Northwell) adopts EnsoSleep as its enterprise-wide standard for sleep study analysis. | A multi-year, system-wide contract with one of the company's existing health system partners. | EnsoData lists partnerships with several large health systems, indicating an ability to sell at the enterprise level [Private Candid Take]. Standardization drives efficiency, a core value proposition. |
| Platform Expansion into Cardio-Respiratory | The AI engine, trained on waveform data, expands beyond sleep to analyze other cardiorespiratory conditions (e.g., COPD, heart failure) from similar monitoring devices. | FDA clearance for a new indication, leveraging the same core technology. | The company's foundational technology analyzes cardiorespiratory waveform data, not just sleep-specific signals [EnsoData, retrieved 2026]. This suggests a logical adjacent market. |
What compounding looks like centers on a data and workflow flywheel. Each new sleep lab deployment generates more waveform data, which can be used to refine the AI models, improving accuracy and potentially expanding the range of detectable disorders. Improved models increase the value proposition, driving further adoption. Furthermore, integration into a health system's electronic health record (EHR) creates workflow lock-in; once scoring is automated and standardized within a provider's clinical pathway, switching costs become high. Evidence of this compounding is early but present: the reported 62-68% time savings are a tangible efficiency gain that should encourage existing customers to expand usage within their networks [EnsoData, retrieved 2026].
The size of the win can be framed by looking at comparable companies and market data. The global sleep apnea diagnostics market alone was valued at $7.72 billion in 2023 and is projected to grow significantly [Grand View Research, 2024]. As a pure-play software company automating a high-cost manual process within this market, EnsoData could command a revenue multiple comparable to other healthcare SaaS platforms. If the Integrated Therapy Pathway scenario plays out and EnsoData captures a material portion of the diagnostic workflow for a growing therapy market valued in the billions, the company's valuation could scale accordingly. This is a scenario-based outcome, not a forecast, but it illustrates the magnitude of the opportunity given the underlying market size and the company's proven automation efficacy.
Data Accuracy: YELLOW -- Core market size and opportunity logic are supported by cited company metrics and investor materials; specific valuation comparables and growth scenario catalysts are extrapolated from available evidence.
Sources
PUBLIC
[EnsoData, retrieved 2026] About Us | https://www.ensodata.com/about-us/
[StartupIntros, retrieved 2026] EnsoData , $10M Raised, Investors, Team & Alternatives | https://www.startuphub.ai/startups/ensodata
[MedCity News, June 2025] AI health startup EnsoData lands $20M to grow sleep apnea team | https://www.bizjournals.com/milwaukee/news/2025/06/25/ensodata-raises-20m-to-expand-commercial-team.html
[EnsoData, June 2025] EnsoData Appoints Dr. Nathaniel Watson as New Chief Medical Officer | https://www.ensodata.com/press_article/ensodata-appoints-dr-nathaniel-watson-as-new-chief-medical-officer/
[Inspire Medical Systems, Jan 2022] Inspire Medical Systems Announces Strategic Investment in EnsoData | https://investors.inspiresleep.com/news-releases/news-release-details/inspire-medical-systems-announces-strategic-investment-ensodata
[Sleep Review, retrieved 2026] EnsoData | https://sleepreviewmag.com/company/ensodata/
[EnsoData Customer Testimonials, retrieved 2026] EnsoData Customer Testimonials | https://www.ensodata.com/customer-testimonials/
[SleepWorld Magazine, May 2025] EnsoData | https://sleepworldmagazine.com/company/ensodata/
[BizTimes, retrieved 2026] EnsoData | https://biztimes.com/company/ensodata/
[Global Market Insights, 2024] Sleep Apnea Diagnostic Devices Market | https://www.gminsights.com/industry-analysis/sleep-apnea-diagnostic-devices-market
[ResMed, retrieved 2026] Somnoware | https://www.resmed.com/en-us/healthcare-professional/products-and-solutions/software/somnoware/
[Nox Medical, retrieved 2026] Noxturnal | https://www.noxmedical.com/products/noxturnal/
[Cerebra, retrieved 2026] Cerebra | https://www.cerebra.ai/
[Grand View Research, 2024] Sleep Apnea Diagnostics Market Size, Share & Trends Analysis Report | https://www.grandviewresearch.com/industry-analysis/sleep-apnea-diagnostics-market
Articles about EnsoData
- EnsoData's FDA-Cleared AI Scored 400 Sleep Clinics a 68% Time Savings — The Madison startup's Series B fuels a push to diagnose the 80% of sleep apnea patients who go undetected.